Hyaskin pharma grade API is supplied for further manufacture into tablets, capsules, granules, oral liquids, and injectable dosage forms. The oral and injectable designations are route-specific rather than molecularly distinct; both are controlled against the current Ph. Eur. and USP monographs for the declared active substance. Release of the oral grade includes identity by infrared spectrophotometry and HPLC retention time, assay of 98.0–102.0% on the dried basis, related substances by a stability-indicating HPLC method, residual solvents according to ICH Q3C Option 1, and elemental impurities according to ICH Q3D. Unspecified related substances are typically limited to not more than 0.10% and total impurities to not more than 0.5%. Particle size is controlled by laser diffraction under USP <429> or Ph. Eur. 2.9.31; the oral grade is normally supplied with a D90 of not more than 45 µm for dry blending and not more than 25 µm for granulation, while injectable formulation may require a D90 of not more than 10 µm where dissolution or suspension uniformity is sensitive to particle surface area. The injectable designation additionally includes bacterial endotoxin and particulate matter data, but it is not a sterile API; sterility is obtained during finished product manufacturing by aseptic filtration or terminal sterilization.

What Route-Specific Criteria Separate the Oral and Injectable Hyaskin Designations?

Endotoxin load, not assay or related-substance profile, is the primary discriminator between oral and injectable Hyaskin grades. For parenteral products, the endotoxin limit is derived from the formula K/M, where K is 5 EU/kg/h for intravenous administration and 0.2 EU/kg/h for intrathecal administration, and M is the maximum bolus dose in mg/kg per hour. A default limit of 0.25 EU/mg cannot be applied without justification if the maximum daily dose is greater than 10 mg/kg/h. Injectable-grade material is therefore released with a bacterial endotoxin value determined by Ph. Eur. 2.6.14 or USP <85>, and the limit on the certificate of analysis must be traceable to the finished product dosage and route. In addition, the injectable designation is tested for particulate contamination after reconstitution or dissolution using light obscuration particle count under Ph. Eur. 2.9.19 or USP <788>, with limits of not more than 6000 particles per container at ≥10 µm and not more than 600 particles per container at ≥25 µm for a parenteral volume appropriate to the dosage form. The oral grade is not routinely released against these methods because the gastrointestinal epithelium does not require the same endotoxin exclusion barrier. This distinction creates an operational boundary: a lot released as oral grade cannot be reassigned to injectable manufacturing without retesting and a documented risk assessment.

For direct compression on a 45-station rotary tablet press, the oral grade is pre-blended with filler-binder, disintegrant, and lubricant before final compression. The feed-frame speed is normally maintained at 20–40 rpm, and main compression force is adjusted between 7 kN and 18 kN depending on tablet diameter, hardness target, and tooling condition. If the API D90 exceeds 45 µm, low-dose blend uniformity can fail USP <905> acceptance value limits because coarse API particles segregate in the feed frame and hopper. Powder flow is evaluated using the compressibility index method of USP <1174>; an index above 25% generally indicates that glidant addition at 0.5–1.0% w/w is required. Magnesium stearate is limited to 1.0–2.0% w/w and total lubrication time is kept below 2–5 min to avoid excessive shear and delayed dissolution. Production-scale experience shows that punch sticking can occur when the API is not pre-dried and the compaction environment exceeds 60% RH; in such cases, the powder bed is pre-dried at 40 °C for 2–6 h in a vacuum tray dryer with nitrogen bleed until Karl Fischer moisture is not more than 0.5%. Content uniformity is assessed by USP <905>, and dissolution is evaluated by USP <711> using apparatus 2 at 50 rpm unless the monograph specifies otherwise.

Micronization, Polymorphic Drift, and Capsule Fill Variability

When the active substance is micronized to a D90 of not more than 25 µm, capsule fill weight variability on dosator machines generally decreases, but cohesive fines can plug the dosing bore if environmental humidity is not controlled. Fill weight relative standard deviation on a high-speed capsule filling line should remain below 3.0%; powder flow is assessed by USP <1174>, and the hopper is fitted with a wall angle of not less than 70° and a vibratory feeder to break bridging. Pre-drying is required at relative humidity above 60% because moisture adsorption alters surface free energy and interparticulate forces, producing caking and flow inconsistency. Micronization also raises the thermodynamic energy of the solid and can induce polymorphic conversion if the product temperature during milling exceeds 40 °C or if the micronizer inlet-air dew point is not controlled. The milled material is therefore retested by X-ray powder diffraction against the reference polymorph and by differential scanning calorimetry for melting onset. A shift in melting onset of more than 2 °C or the appearance of a new diffraction peak can indicate a polymorphic change that may alter dissolution and compactability even when assay and related substances remain within specification. Capsule dissolution is tested by USP <711> with sinker devices if the capsule shell adheres to the vessel wall.

Technical-grade material with the same apparent chemical name is not interchangeable with Hyaskin pharma grade API. The non-compendial material frequently lacks a full ICH Q3D elemental impurity risk assessment and may contain nitrosamine impurities above the 18 ng/day total threshold applied under ICH M7. Residual solvent control is also inferior: class 2 solvents such as methylene chloride are often present above the 600 ppm limit assigned by ICH Q3C, and class 1 solvents such as benzene may be present above the 2 ppm limit. Even among compendial-grade APIs, differences in crystal morphology, particle aspect ratio, hydration state, and surface energy can require re-validation of blending time, compression speed, or encapsulation parameters even when chemical specifications are equivalent. A difference in particle D90 from 25 µm to 45 µm may not affect a raw-material certificate of analysis but can alter content uniformity and dissolution profile in a low-dose finished product. For this reason, the product is evaluated not only by pharmacopoeial tests but also by application-specific powder rheology and compactability data.

When Terminal Sterilization or Aseptic Filtration Is Applied to Injectable Hyaskin

In injectable manufacture, the oral-grade lot is not substituted for the injectable designation without a documented bridging study. The API is dissolved in Water for Injection at 20–25 °C, and the solution is passed through a 0.22 µm polyvinylidene fluoride or polyethersulfone membrane filter. Terminal steam sterilization at 121 °C for 15 min is acceptable only when the formulation has demonstrated not more than 2.0% total degradation in forced degradation studies over the intended pH range. If the active substance is thermolabile, aseptic filtration is used, but the holding time between dissolution and filtration is limited to 4 h at 15–25 °C to minimize bioburden challenge. Dissolved oxygen is maintained below 0.2 mg/L by nitrogen sparging when oxidative degradation is a known pathway. Silicone oil from pump tubing can introduce subvisible particles; platinum-cured silicone or fluoropolymer tubing is used for transfer lines. The formulation pH is held within the validated stability range, commonly 3.0–8.0 for hydrolytically sensitive molecules, but the exact range must be established by forced degradation under ICH Q1A(R2) conditions. If the finished injection is a suspension, particle size after autoclaving is retested by USP <429> to confirm that crystal growth or agglomeration has not occurred. Published data for this specific configuration are limited; therefore, terminal sterilization and aseptic process simulations must be validated on the actual filling line using media fills and fill-weight checks at not less than ±2% of target fill volume.

Granule and sachet manufacturing requires a different set of process boundary conditions because the API is exposed to water, heat, and shear during binder addition. In a top-spray fluid-bed granulator, inlet-air temperature is set at 50–70 °C, product temperature is maintained at 30–40 °C, and spray rate is adjusted to keep the granule moisture content between 1.0% and 3.0% by loss on drying. If the product temperature exceeds 40 °C, drying-induced amorphous content may increase, and the resulting glass transition shift can cause caking during storage. The dried granules are milled through a 1.0 mm screen and blended with extragranular disintegrant and lubricant. Blend uniformity is tested by USP <905>, and granule flow is measured by USP <1174> compressibility index. Residual moisture is confirmed by Karl Fischer titration after drying, with a typical limit of not more than 0.5–1.5% depending on the formulation. If the granulation solvent contains ethanol or isopropyl alcohol, headspace gas chromatography is used to confirm that residual solvent levels are below the limits assigned by ICH Q3C.

Granule Drying Endpoints Are Not Equivalent to Powder Loss-on-Drying Limits

Granule drying endpoint is defined by the combination of loss-on-drying value, product temperature, and exhaust-air dew point, not by loss-on-drying alone. In a fluid-bed dryer, the drying cycle is terminated when the exhaust-air relative humidity remains below 15% for three consecutive readings taken at 5 min intervals, and the product temperature has reached 35–40 °C. Premature discharge of granules with residual moisture above 2.5% can cause tablet picking, poor flow, and increased water activity that supports microbial growth. Overdrying below 0.5% moisture can generate friable granules and increase electrostatic charging, which produces weight variation on the tablet press or capsule filler. The drying endpoint is therefore linked to downstream equipment performance: a loss-on-drying value of 1.0–2.0% is commonly targeted for aqueous granulation, while a value of 0.5–1.0% is used when the lubricant is sensitive to moisture. If the granule is filled into hard gelatin capsules, the fill weight and disintegration time are tested by USP <2040> or the general disintegration method, and the capsule moisture is controlled to avoid shell brittleness or softening.

In injectable solution reconstitution, the Hyaskin injectable grade is characterized not only by chemical purity but also by subvisible particle and endotoxin behavior after dilution. The product is dissolved in water for injection at 20–25 °C, and the resulting solution is evaluated by Ph. Eur. 2.9.19 or USP <788> before and after terminal sterilization. If the formulation contains the API in a concentration above 10 mg/mL, viscosity may exceed 2 mPa·s, and filtration through a 0.22 µm membrane may require a transmembrane pressure above 0.5 bar; filter selection is then verified by bacterial retention testing and extractable studies under USP <1665>. The injectable grade should not be exposed to repeated freeze-thaw cycles if the finished product is a lyophilized cake; the reconstituted solution is tested for particulate matter and assay after reconstitution with an appropriate diluent. If the API is moisture-sensitive, the lyophilization cycle is designed with a primary drying shelf temperature of -20 °C to -10 °C and a chamber pressure of 50–150 mTorr, but published data for this exact formulation may be limited and require cycle development on the specific freeze-dryer geometry.

Differences from other API sources become most evident in high-shear wet granulation. A source with a broad particle size distribution may require higher water volume to reach the same granule endpoint, while a source with a narrow distribution and high fine fraction may over-granulate at the same water addition. In high-shear mixers, impeller speed is maintained at 100–300 rpm and chopper speed at 1500–3000 rpm for wet massing times of 1–3 min; longer wet massing can produce dense granules that resist disintegration. The product is therefore characterized by particle size distribution, specific surface area, and flow function coefficient, not only by compendial chemical tests. If a replacement API source is considered, the finished product must be revalidated for blend uniformity, content uniformity, dissolution, and stability under ICH Q1A(R2) conditions because crystal habit and surface energy differences can persist even after granulation. No conclusion or equivalency statement is made without comparative process data.